Sodium Glucose Cotransporter 2 Inhibitors, Amputation Risk, and Fracture Risk

被引：11
|
作者：
Arnott, Clare [1 ,2 ,3 ]
Fletcher, Robert A. [1 ]
Neal, Bruce [1 ,4 ]
机构：
[1] Univ New South Wales, George Inst Global Hlth, Level 5,1 King St, Sydney, NSW 2042, Australia
[2] Royal Prince Alfred Hosp, Dept Cardiol, Sydney, NSW, Australia
[3] Univ Sydney, Sydney Med Sch, Sydney, NSW, Australia
[4] Imperial Coll London, Dept Epidemiol & Biostat, London, England
来源：
HEART FAILURE CLINICS | 2022年 / 18卷 / 04期
关键词：
SGLT2; inhibitors; Meta-analysis; Amputation; Fracture; TYPE-2; CANAGLIFLOZIN;
D O I：
10.1016/j.hfc.2022.03.008
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：645 / 654
页数：10
相关论文
共 50 条
  • [1] Sodium Glucose Cotransporter 2 Inhibitors and Amputation Risk Achilles' Heel or Opportunity for Discovery?
    Bonaca, Marc P.
    Beckman, Joshua A.
    CIRCULATION, 2018, 137 (14) : 1460 - 1462
  • [2] Sodium-Glucose Cotransporter-2 Inhibitors and the Risk of Amputation: What Is Currently Known?
    Misher, Anne
    Ampuero, Andrea
    Phan, Rebecca
    Aziz, Soma
    Ebong, Eti
    Braich, Judy
    Dyches, Kristin
    Southwood, Robin
    AMERICAN JOURNAL OF THERAPEUTICS, 2021, 28 (01) : E96 - E110
  • [3] Sodium–glucose cotransporter 2 inhibitors and risk of nephrolithiasis
    Kasper B. Kristensen
    Daniel P. Henriksen
    Jesper Hallas
    Anton Pottegård
    Lars C. Lund
    Diabetologia, 2021, 64 : 1563 - 1571
  • [4] Sodium glucose cotransporter 2 inhibitors and gout risk
    Lai, Shih-Wei
    Hwang, Bing-Fang
    Liu, Chiu-Shong
    Liao, Kuan-Fu
    CLINICAL RHEUMATOLOGY, 2024, 43 (02) : 835 - 836
  • [5] Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Amputation Results and Challenges From the Real World
    Fralick, Michael
    Patorno, Elisabetta
    Fischer, Michael A.
    JAMA INTERNAL MEDICINE, 2018, 178 (09) : 1199 - 1200
  • [6] Sodium-glucose cotransporter 2 inhibitors and risk of nephrolithiasis
    Kristensen, Kasper B.
    Henriksen, Daniel P.
    Hallas, Jesper
    Pottegard, Anton
    Lund, Lars C.
    DIABETOLOGIA, 2021, 64 (07) : 1563 - 1571
  • [7] Comment on “Sodium glucose cotransporter 2 inhibitors and gout risk”
    Shih-Wei Lai
    Bing-Fang Hwang
    Chiu‑Shong Liu
    Kuan-Fu Liao
    Clinical Rheumatology, 2024, 43 : 835 - 836
  • [8] Fracture Risk of Sodium-Glucose Cotransporter-2 Inhibitors in Chronic Kidney Disease
    Cowan, Andrea
    Jeyakumar, Nivethika
    Kang, Yuguang
    Dixon, Stephanie N.
    Garg, Amit X.
    Naylor, Kyla
    Weir, Matthew A.
    Clemens, Kristin K.
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 17 (06): : 835 - 842
  • [9] Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Below-Knee Amputation: A Multicenter Observational Study
    Yu, Oriana Hoi Yun
    Dell'Aniello, Sophie
    Shah, Baiju R.
    Brunetti, Vanessa C.
    Daigle, Jean-Marc
    Fralick, Michael
    Douros, Antonios
    Hu, Nianping
    Alessi-Severini, Silvia
    Fisher, Anat
    Bugden, Shawn C.
    Ronksley, Paul E.
    Filion, Kristian B.
    Ernst, Pierre
    Lix, Lisa M.
    DIABETES CARE, 2020, 43 (10) : 2444 - 2452
  • [10] Fracture Risk in Patients Using Sodium-Glucose Cotransporter 2 Inhibitors: A Real-World Study
    Abrahami, Devin
    Douros, Antonios
    Yin, Hui
    Yu, Oriana Hoi Yun
    Azoulay, Laurent
    DIABETES, 2019, 68
12345